# Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

> **NCT01406639** · PHASE1 · WITHDRAWN · sponsor: **University of California, San Diego**

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia (HHT)
- Nosebleeds

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01406639
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-07
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to lack of study population.
- **Last updated:** 2013-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01406639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01406639, "Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT01406639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*